Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).

Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses

Current status of clinical trials assessing oncolytic virus therapy for urological cancers

Recent advances in immuno-oncology and its application to urological cancers

Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer

[Combined radiotherapy and endovascular x-ray therapy for invasive cancer of the urinary bladder]

In vitro induction of a bladder cancer-specific T-cell response by mRNA-transfected dendritic cells

Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide

Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts